New England Research & Management Inc. Sells 5,011 Shares of Agilent Technologies, Inc. $A

New England Research & Management Inc. reduced its position in shares of Agilent Technologies, Inc. (NYSE:A) by 36.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,764 shares of the medical research company’s stock after selling 5,011 shares during the quarter. New England Research & Management Inc.’s holdings in Agilent Technologies were worth $1,125,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Capital A Wealth Management LLC boosted its stake in Agilent Technologies by 10,600.0% in the second quarter. Capital A Wealth Management LLC now owns 214 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 212 shares during the last quarter. Ransom Advisory Ltd acquired a new stake in shares of Agilent Technologies during the first quarter worth $32,000. Central Pacific Bank Trust Division bought a new stake in Agilent Technologies in the second quarter valued at about $33,000. State of Wyoming acquired a new position in Agilent Technologies in the second quarter valued at about $35,000. Finally, WFA of San Diego LLC bought a new position in Agilent Technologies during the second quarter worth about $61,000. Institutional investors and hedge funds own 87.41% of the company’s stock.

Agilent Technologies Trading Up 0.7%

Shares of Agilent Technologies stock opened at $140.62 on Tuesday. The stock has a market cap of $39.86 billion, a P/E ratio of 30.77, a P/E/G ratio of 4.05 and a beta of 1.27. The company has a quick ratio of 1.52, a current ratio of 1.96 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $145.57 and its 200-day moving average is $129.47. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $160.27.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.01. The business had revenue of $1.86 billion during the quarter, compared to the consensus estimate of $1.83 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. Agilent Technologies’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $1.46 EPS. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. Equities research analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 28th. Investors of record on Tuesday, January 6th will be paid a $0.255 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.25. The ex-dividend date is Tuesday, January 6th. This represents a $1.02 dividend on an annualized basis and a yield of 0.7%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.32%.

Insider Transactions at Agilent Technologies

In related news, VP Rodney Gonsalves sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the sale, the vice president directly owned 31,846 shares in the company, valued at $4,935,811.54. The trade was a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Padraig Mcdonnell sold 911 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total transaction of $130,491.64. Following the completion of the transaction, the chief executive officer owned 32,058 shares in the company, valued at $4,591,987.92. This trade represents a 2.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 16,401 shares of company stock valued at $2,468,962. 0.26% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on Agilent Technologies from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Tuesday, November 25th. Wells Fargo & Company boosted their price objective on shares of Agilent Technologies from $150.00 to $175.00 and gave the company an “overweight” rating in a report on Tuesday, November 25th. Bank of America increased their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “neutral” rating in a report on Tuesday, November 25th. Evercore ISI upped their price objective on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a research report on Tuesday, October 7th. Finally, Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $161.77.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.